(Q38430335)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

A phase I study of cabozantinib (XL184) in patients with renal cell cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

T K Choueiri

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

S K Pal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

D F McDermott

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

S Morrissey

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

K C Ferguson

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

J Holland

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

W G Kaelin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

J P Dutcher

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

publication date

14 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

1603-1608

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth

18 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Targeting the Met signaling pathway in renal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Metastatic renal cell carcinoma: many treatment options, one patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Kinase requirements in human cells: III. Altered kinase requirements in VHL-/- cancer cells detected in a pilot synthetic lethal screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Pazopanib versus sunitinib in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Cabozantinib in progressive medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Clinical features of metastatic bone disease and risk of skeletal morbidity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

MET and VEGF: synergistic targets in castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU184

Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24827131

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/ANNONC/MDU184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

PubMed publication ID

24827131

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24827131%20AND%20SRC:MED&resulttype=core&format=json